Cargando…
Eculizumab treatment of atypical haemolytic uraemic syndrome: results from the largest prospective clinical trial to date
Autores principales: | weekers, LE, Campistol, JM, Espinosa, M, Gaber, AO, Menne, J, Minetti, E, Provot, F, Rondeau, E, Ogawa, M, Bedrosian, CL, hourmant, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068163/ http://dx.doi.org/10.1186/cc13295 |
Ejemplares similares
-
Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
por: Menne, Jan, et al.
Publicado: (2018) -
Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
por: Durán, Carlos E., et al.
Publicado: (2012) -
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013)